Selective serotonin reuptake inhibitors vs placebo
Frequency of attacks Per week (over 2 weeks) · primary Raynaud's phenomenon
1 finding from 1 review
- no estimate extracted1 study · 41 participantsVery low
Findings
What do systematic reviews say?
31 questions · 32 findings · 6 reviews
No studies found 3 · 9.4%GRADE not reported 3 · 9.4%Very low 19 · 59.4%Low 2 · 6.3%Moderate 5 · 15.6%High 0 · 0%
Selective serotonin reuptake inhibitors vs placebo
Severity of attacks · primary Raynaud's phenomenon
1 finding from 1 review
- no estimate extracted1 study · 41 participantsVery low
Selective serotonin reuptake inhibitors vs placebo
Duration of attacks per day (minutes) · primary Raynaud's phenomenon
1 finding from 1 review
- no estimate extracted1 study · 41 participantsVery low
Selective serotonin reuptake inhibitors vs placebo
QoL · primary Raynaud's phenomenon
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Selective serotonin reuptake inhibitors vs placebo
Proportion of participants with adverse effects ‐ measured over 8 weeks · primary Raynaud's phenomenon
It is very uncertain whether selective serotonin reuptake inhibitors changes adverse events (over 4 weeks) compared with placebo (very low certainty).
1 finding from 1 review
- RR 1.54 [0.89, 2.66]1 study · 41 participantsVery low
Selective serotonin reuptake inhibitors vs placebo
RCS · primary Raynaud's phenomenon
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Selective serotonin reuptake inhibitors vs cognitive behavioural therapy
> 50% reduction in depressive symptoms · people with epilepsy and depression
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
Selective serotonin reuptake inhibitors vs cognitive behavioural therapy
Depressive symptoms · people with epilepsy and depression
1 finding from 1 review
- no estimate extracted15 participantsVery low
Selective serotonin reuptake inhibitors vs cognitive behavioural therapy
Seizure frequency · people with epilepsy and depression
1 finding from 1 review
- no estimate extracted15 participantsVery low
Selective serotonin reuptake inhibitors vs cognitive behavioural therapy
Treatment withdrawal · people with epilepsy and depression
It is very uncertain whether selective serotonin reuptake inhibitors changes withdrawals compared with cognitive behavioural therapy (very low certainty).
1 finding from 1 review
- RR 0.44 [0.05, 3.85]15 participantsVery low
Selective serotonin reuptake inhibitors vs cognitive behavioural therapy
Cognitive function · people with epilepsy and depression
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
Selective serotonin reuptake inhibitors vs cognitive behavioural therapy
Post‐treatment quality of life (QOLIE‐31 score, which has a range of 0‐200, with higher score indicates better quality of life) ( · people with epilepsy and depression
1 finding from 1 review
- no estimate extracted15 participantsVery low
Selective serotonin reuptake inhibitors vs cognitive behavioural therapy
Adverse effects ‐ adverse event profile · people with epilepsy and depression
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)
Dropout · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes study dropouts at 6‐12 weeks compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
- RR 0.81 [0.51, 1.3]2 studies · 64 participantsVery low
Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)
Adverse effects during antidepressant treatment period (0‐12 weeks) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes adverse effects during antidepressant treatment period (0‐12 weeks) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
- RR 1.05 [0.67, 1.64]1 study · 14 participantsVery low
Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)
Improvement in depression at 6‐12 weeks: HAM‐D score (continuous) · adults living with HIV and depression
1 finding from 1 review
- no estimate extracted1 study · 14 participantsVery low
Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)
Improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
- RR 0.89 [0.54, 1.46]2 studies · 64 participantsVery low
Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)
Improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
- RR 1.24 [0.68, 2.24]2 studies · 64 participantsVery low
Selective serotonin reuptake inhibitors vs placebo
Outcomes (2‐6 months post‐treatment) · adults with panic disorder
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Selective serotonin reuptake inhibitors vs placebo
Failure to respond at endpoint (6‐12 weeks) · adults with panic disorder
Selective serotonin reuptake inhibitors may leads to lower failure to respond compared with placebo (low certainty).
1 finding from 1 review
- RR 0.75 [0.67, 0.84]21 studies · 4000 participantsLow